BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q4 EPS

February 16, 2012 6:31 AM EST Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $7.34 million.

BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment